50
Participants
Start Date
February 26, 2014
Primary Completion Date
February 22, 2017
Study Completion Date
September 5, 2019
axitinib
Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
crizotinib
Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
axitinib
Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
crizotinib
Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
axitinib
Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
crizotinib
Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland
Investigational Drug Services IUHSCC, Indianapolis
IU Health University Hospital, Indianapolis
Wayne State University, Dept. of Oncology, Detroit
University Station Ophthalmology Clinic, Madison
University of Wisconsin Hospital and Clinics, Madison
University of Minnesota Health Clinics and Surgery Center, Minneapolis
University of Minnesota Medical Center, Fairview IDS Pharmacy, Minneapolis
University of Minnesota Medical Center, Fairview, Minneapolis
University of Minnesota Physicians Masonic Cancer Center, Minneapolis
University of Chicago Medical Center, Chicago
Huntsman Cancer Hospital, Salt Lake City
Huntsman Cancer Institute, Salt Lake City
John A Moran Eye Center, Salt Lake City
Massachusetts General Hospital, Boston
St Bartholomew's Hospital - Barts Health NHS Trust, London
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, London
Lead Sponsor
Pfizer
INDUSTRY